Altimmune to Participate at Two Upcoming Investor Conferences
Get Alerts ALT Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences:
- Evercore ISI 5th Annual HealthCONx Virtual ConferenceTuesday, November 29, 2022Fireside chat at 10:55 am Eastern Time
- Piper Sandler 34th Annual Healthcare Conference in New York, NYThursday, December 1, 2022Fireside chat at 10:00 am Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Richard EisenstadtChief Financial OfficerPhone: 240-654-1450[email protected]
Source: Altimmune, IncSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex, Inc. Announces Pricing of Upsized $300 Million Convertible Senior Notes Offering
- HashKey Global Partners with Solidus Labs to Elevate Real-Time Trade Surveillance
- Jesper and Jesse Will Work Together Again at rabbit!
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!